Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59

Showing 26-50 of 59 citing articles:

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, et al.
Drugs in R&D (2024) Vol. 24, Iss. 1, pp. 97-108
Open Access | Times Cited: 2
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women
Priska Kaufmann, Clemens Muehlan, Marion Anliker‐Ort, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1278-1287
Open Access | Times Cited: 2
Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study
Naohisa Uchimura, Mitsutaka Taniguchi, Yu Ariyoshi, et al.
Sleep Medicine (2024) Vol. 122, pp. 27-34
Open Access | Times Cited: 2
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 810-819
Open Access | Times Cited: 16
Daridorexant for the treatment of insomnia disorder: findings and implications
Jéssica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1749-1761
Closed Access | Times Cited: 12
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects
Clemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 40, Iss. 2, pp. 157-166
Closed Access | Times Cited: 17
Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
Aya Futamura, Ryo Suzuki, Yunoshin Tamura, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 13, pp. 115489-115489
Closed Access | Times Cited: 15
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob Zuiker, et al.
CNS Drugs (2020) Vol. 34, Iss. 12, pp. 1253-1266
Closed Access | Times Cited: 15
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Benjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2132-2138
Open Access | Times Cited: 13
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats
Michel A. Steiner, Michael Toeroek-Schafroth, Maria Elena Giusepponi, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 12, pp. 1249-1260
Open Access | Times Cited: 5
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulč, et al.
Clinical and Experimental Pharmacology and Physiology (2020) Vol. 47, Iss. 11, pp. 1843-1849
Closed Access | Times Cited: 13
A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker
Christine Huynh, Andrea Henrich, Daniel S. Strasser, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 109, Iss. 6, pp. 1648-1659
Closed Access | Times Cited: 12
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
Andreas Krause, Dominik Lott, Janneke M. Brussee, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 12, Iss. 1, pp. 74-86
Open Access | Times Cited: 8
The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future
Ad F. Roffel, Ewoud J. van Hoogdalem
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies
Makoto Uchiyama, Kazuo Mishima, Tomoko Yagi, et al.
Journal of Sleep Research (2024)
Open Access | Times Cited: 1
Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis
Siddhartha Dutta, Shubha Singhal, Rima Shah, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 12, pp. 1237-1251
Open Access | Times Cited: 3
Non‐Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece
Graeme Young, Douglas K. Spracklin, Alexander D. James, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 5, pp. 931-938
Open Access | Times Cited: 3
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
Christine Huynh, Swen Seeland, Jérôme Segrestaa, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development
Simon Wong, Shuguang Ma
Elsevier eBooks (2023), pp. 137-174
Closed Access | Times Cited: 2
Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878
Shunsuke Maehara, Natsuko Yuge, Chika Higashi, et al.
Neuropsychopharmacology Reports (2020) Vol. 40, Iss. 2, pp. 182-189
Open Access | Times Cited: 4

Scroll to top